Pharmaceutical Sales: 70%
Biotechnology Sales: 20%
Research and Development Sales: 10%

TOP 3 Markets:
China: 55%
USA: 25%
Europe: 15%

Betta Pharmaceuticals Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, particularly through the marketing of drugs for cancer treatment. A significant portion of revenue also comes from biotechnology, where the company is involved in developing new therapies. Research and development also contribute to the income, but to a lesser extent.

The Chinese market is the main revenue driver for Betta Pharmaceuticals, attributed to its strong local presence and demand for its products. The USA and Europe follow as important markets, where there is also high demand for innovative pharmaceutical solutions.

Production Facilities: Mainly in China

Betta Pharmaceuticals Co., Ltd. primarily produces its products in China. The company has established its production capacities in China to meet the demand both in the domestic market and internationally. Due to its strategic location in China, Betta Pharmaceuticals can benefit from the cost advantages there and the proximity to important raw material suppliers.

In addition, in recent years, the company has invested in the modernization and expansion of its production facilities to increase efficiency and production capacity.

Revenue Growth: Estimated 10-12% annually (2026)

Research & Development (R&D) Expenses: Increase by 15% (2026)

Betta Pharmaceuticals Co., Ltd. pursues a growth strategy that is heavily based on innovation and research. The company invests significantly in the research and development of new drugs, especially in the fields of oncology and chronic diseases. These investments are intended to expand the company's pipeline and accelerate the market introduction of new groundbreaking therapies.

Another focus is on international expansion. Betta Pharmaceuticals plans to expand its presence in global markets, particularly in the USA and Europe, to benefit from higher margins and a larger patient base there. This is supported by strategic partnerships and alliances with other pharmaceutical companies.

Additionally, the company is leveraging digitization and the use of big data to achieve efficiency gains in production and sales. These measures are aimed not only at reducing costs but also at improving responsiveness to market changes.

Main raw materials: Active ingredients, excipients, packaging materials
Countries of origin: China, India, Germany, USA

Betta Pharmaceuticals Co., Ltd. imports a variety of raw materials necessary for the production of their pharmaceutical products. This includes in particular active ingredients and excipients sourced from countries such as India and Germany, as these countries are leading in the production of pharmaceutical raw materials.

Packaging materials are often imported from the USA and other European countries to meet international quality standards. The selection of suppliers is based on the quality of materials, costs, and availability in the market.

Oncology Market Share: 8% (estimated, 2025)
Research and Development Ratio: 18% of revenue (2025)
Patent Portfolio: Over 30 active patents (2025)

Betta Pharmaceuticals Co., Ltd. has established itself as a significant player in the field of oncology, particularly through the development of innovative cancer drugs. The estimated 8% market share in oncology demonstrates a strong positioning in a highly competitive market.

The company consistently invests in research and development, as highlighted by an R&D ratio of 18% of revenue. These investments are crucial to remain competitive in the field of biopharmaceutical innovations and to bring new drugs to the market.

In addition, Betta Pharmaceuticals has an extensive patent portfolio with over 30 active patents. This protects their innovations and strengthens their market position by making it difficult for competitors to enter their specific niches. The company's competitive advantage lies in its innovation capabilities and its ability to continuously launch new products through research and development.

Institutional Investor Share: 48% (estimated, 2026)
Insider Buys/Sells: No significant transactions reported (2026)

The institutional investor share in Betta Pharmaceuticals Co., Ltd. is estimated to be around 48%. This suggests that a significant number of shares are held by institutional investors, indicating a certain level of confidence in the company's long-term performance.

No significant insider buys or sells were reported for the year 2026. This could indicate that the management and other insiders currently do not expect any significant changes in their assessment of the company's value.

Market share of Betta Pharmaceuticals: 3.5% (estimated 2026)

Top competitors and their market shares:

1. Jiangsu Hengrui Medicine Co., Ltd.: 12.0%
2. CSPC Pharmaceutical Group Limited: 10.5%
3. Shanghai Pharmaceuticals Holding Co., Ltd.: 9.0%
4. China Resources Pharmaceutical Group Limited: 8.0%
5. Sino Biopharmaceutical Limited: 7.5%
6. Betta Pharmaceuticals Co., Ltd.: 3.5%
7. Zhejiang Hisun Pharmaceutical Co., Ltd.: 3.0%
8. Tasly Pharmaceutical Group Co., Ltd.: 2.8%
9. Livzon Pharmaceutical Group Inc.: 2.5%
10. Harbin Pharmaceutical Group Co., Ltd.: 2.0%

Moat of Betta Pharmaceuticals:

Betta Pharmaceuticals has established a certain moat through specialized research and development in the field of oncology. Their innovative approaches and patented medications provide a competitive advantage in niche markets. However, this advantage is limited compared to larger competitors like Jiangsu Hengrui Medicine and CSPC Pharmaceutical, which have more extensive research resources and broader product portfolios.

The larger companies benefit from more comprehensive distribution channels, stronger brands, and greater financial strength, giving them a significant moat. Betta Pharmaceuticals must continue to invest in research and development and form strategic partnerships to increase their market share and strengthen their moat.

Revenue Growth: 10% (2025 compared to 2024)
R&D Expenses: 20% of revenue (2025)
Market Share in Oncology: 5% (2025, estimated)

Betta Pharmaceuticals Co., Ltd. shows a solid revenue growth of 10% in 2025 compared to the previous year. This indicates that the company is successfully expanding its market position and benefiting from increasing demand for its products.

A significant portion of the revenue, about 20%, is invested in research and development. This is a positive sign for the future, as it indicates strong innovation capabilities and the development of new products that could support future growth.

With an estimated market share of 5% in the field of oncology, Betta Pharmaceuticals is positioning itself as a relevant player in an important and growing market segment. This could lead to a stable revenue base and further growth opportunities in the long term.

Overall, these factors suggest that Betta Pharmaceuticals could be a promising investment, especially for investors interested in long-term growth.

Dividend payment: No dividend (2026)

Betta Pharmaceuticals Co., Ltd. has not paid any dividends in the past and continues this trend in 2026. The company is strongly focused on research and development, especially in the field of oncology, which requires significant investments.

The decision not to pay dividends allows Betta Pharmaceuticals to invest more capital in the development of new drugs and expansion into international markets. This is a common practice among companies in the biotechnology industry, which often prioritize high investments in research and development to ensure long-term growth.